CLAIMS

1. A stable pharmaceutically acceptable salt of noribogaine ansolvate.

2. The stable salt of noribogaine ansolvate of claim 1, wherein the salt is a hydrochloride salt.

3. The salt of claim 2, which is crystalline.

4. The crystalline salt of claim 3, characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 12.1°, 13.5°, 14.0°, 15.0°, 15.8°, 18.0°, 20.0°, 20.9°, 21.1°, 22.0°, 22.8°, 23.0°, 26.5, and 31.5°2θ (each ±0.2 °2θ).

5. The crystalline salt of claim 3, which shows substantially no thermal transitions under 300°C in its differential scanning calorimetry thermogram.

6. The crystalline salt of claim 3, which shows substantially no weight loss at a temperature under 300°C in its thermogravimetric analysis thermogram.

7. The crystalline ansolvate salt of claim 3, which has a density that is at least 3% and up to 20% greater than the density of a solvated crystalline hydrochloride salt of noribogaine.

8. The crystalline ansolvate salt of claim 3, which has a unit cell volume of less than about 1800 cubic angstrom, or less than about 1750 cubic angstrom, or less than 1700±2% cubic angstrom.

9. A crystalline noribogaine hydrochloride solvate polymorph characterized by about 4% weight loss at temperatures under 125°C in its differential scanning calorimetry thermogram.

10. The crystalline solvate polymorph of claim 9 characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 9,7, 10.5, 12.2, 13.2, 13.8, 16.1, 16.5, 17.5, 18, 19.5, 21.5, 22.2, 23, 24.5, 25.2 2θ (each ±0.2 °2θ).

11. The stable ansolvate salt of noribogaine of claim 1, wherein the salt is a sulfate salt.

12. The salt of claim 11, which is crystalline.

13. The crystalline salt of claim 12 characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 8.5°, 11.4°, 12.0°, 13.3, 15.4°, 16.6°, 17.2°, 18.3°2θ, 20.6, 21.0, and 21.5 (each ±0.2 °2θ).

14. A composition comprising the stable noribogaine ansolvate salt of any one of claims 1 – 8 and 11-14.

15. The composition of claim 14, further comprising a pharmaceutically acceptable excipient.

16. A crystalline polymorph of a phosphate salt of noribogaine.

17. A method of treating a patient to alleviate nociceptive pain in the absence of the treatment of drug dependence or drug abuse and in the absence of any concomitant opioid analgesic therapy, comprising: administering systemically to said patient a pharmaceutical composition comprising effective amount of the stable noribogaine salt ansolvate of any one of claims 1– 8 and 11-14, or the composition of claim 14 or 15, to said patient effective to reduce or eliminate said nociceptive pain in said patient.

18. A method of treating a patient to alleviate nociceptive pain in the absence of the treatment of drug dependence or drug abuse and in the absence of any concomitant opioid analgesic therapy, comprising: administering systemically to said patient a pharmaceutical composition comprising effective amount of the stable noribogaine salt ansolvate of claim 1, or the phosphate salt of claim 16, or the composition of claim 14 or 15, to said patient effective to reduce or eliminate said nociceptive pain in said patient.

CLAIMS

1. A stable pharmaceutically acceptable salt of noribogaine ansolvate.

2. The stable salt of noribogaine ansolvate of claim 1, wherein the salt is a hydrochloride salt.

3. The salt of claim 2, which is crystalline.

4. The crystalline salt of claim 3, characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 12.1°, 13.5°, 14.0°, 15.0°, 15.8°, 18.0°, 20.0°, 20.9°, 21.1°, 22.8°, 23.0°, 26.5°, and 31.5°2θ (each ±0.2 °2θ).

5. The crystalline salt of claim 3, which shows substantially no thermal transitions under 300°C in its differential scanning calorimetry thermogram.

6. The crystalline salt of claim 3, which shows substantially no weight loss at a temperature under 300°C in its thermogravimetric analysis thermogram.

7. The crystalline ansolvate salt of claim 3, which has a density that is at least 3% and up to 20% greater than the density of a solvated crystalline hydrochloride salt of noribogaine.

8. The crystalline ansolvate salt of claim 3, which has a unit cell volume of less than about 1800 cubic angstrom, or less than about 1750 cubic angstrom, or less than 1700±2% cubic angstrom.

9. A crystalline noribogaine hydrochloride solvate polymorph characterized by about 4% weight loss at temperatures under 125°C in its differential scanning calorimetry thermogram.

10. The crystalline solvate polymorph of claim 9 characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 9.7, 10.5, 12.2, 13.2, 13.8, 16.1, 16.5, 17.5, 18, 19.5, 21.5, 22.2, 23, 24.5, 25.2 2θ (each ±0.2 °2θ).

11. The stable ansolvate salt of noribogaine of claim 1, wherein the salt is a sulfate salt.

12. The salt of claim 11, which is crystalline.

13. The crystalline salt of claim 12 characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 8.5°, 11.4°, 12.0°, 13.3, 15.4°, 16.6°, 17.2°, 18.3°2θ, 20.6, 21.0, and 21.5 (each ±0.2 °2θ).

14. A crystalline polymorph of a phosphate salt of noribogaine.